［1］Fontanella C,Fanotto V,Rihawi K,et al.Skeletal metastases from breast cancer:pathogenesis of bone tropism and treatment strategy［J］.Clin Exp Metastasis,2015,32(8):819-833.
［2］Zheng Y,Wu CX,Zhang ML.The epidemic and characteristics of female breast cancer in China［J］.China Oncol,2013,23(8):561-569.［郑莹,吴春晓,张敏璐.乳腺癌在中国的流行状况和疾病特征［J］.中国癌症杂志,2013,23(8):561-569.］
［3］Rossi L,Pagani O.The modern landscape of endocrine therapy for premenopausal women with breast cancer［J］.Breast Care (Basel),2015,10:312-315.
［4］Wang X.Study on the compliance of endocrine therapy in postmenopausal breast cancer patients［D］.Hebei Medical University,2017.［王旭.绝经后乳腺癌患者内分泌治疗依从性研究［D］.河北医科大学，2017.］
［5］Friese CR,Pini TM,Li Y,et al.Adjuvant endocrine therapy initiation and persistence in a diverse sample of patients with breast cancer［J］.Breast Cancer Res Treat,2013,138(3):931-939.
［6］Gong P.Hormone receptor change during treatment and endocrine therapy compliance in breast cancer［D］.Shandong University,2017:1-95.［公娉.乳腺癌治疗过程中激素受体状态的改变及内分泌治疗依从性的研究［D］.山东大学,2017:1-95.］
［7］Pistelli M,Mora AD,Ballatore Z,et al.Aromatase inhibitors in premenopausal women with breast cancer:the state of the art and future prospects［J］.Curr Oncol,2018,25(2):e168-e175.
［8］Iwata H,Masuda N,Ohno S,et al.A randomized,double-blind,controlled study of exemestane versus anastrozole for the first-line treatment of postmenopausal Japanese women with hormone-receptor-positive advanced breast cancer［J］.Breast Cancer Res Treat,2013,139(2):441-451.
［9］Goss PE,Ingle JN,Pritchard KI,et al.Exemestane versus anastrozole in postmenopausal women with early breast cancer: NCIC CTG MA.27-a randomized controlled phase III trial［J］.J Clin Oncol,2013,31(11):1398-1404.
［10］De Placido S,Gallo C,De Laurentiis M,et al.Adjuvant anastrozole versus exemestane versus letrozole,upfront or after 2 years of tamoxifen,in endocrine-sensitive breast cancer (FATA-GIM3):a randomised,phase 3 trial［J］.Lancet Oncol,2018,19(4):474-485.
［11］Campos SM,Guastalla JP,Subar M,et al.A comparative study of exemestane versus anastrozole in patients with postmenopausal breast cancer with visceral metastases［J］.Clin Breast Cancer,2009,9(1):39-44.
［12］Llombart-Cussac A,Ruiz A,Antón A,et al.Exemestane versus anastrozole as front-line endocrine therapy in postmenopausal patients with hormone receptor-positive,advanced breast cancer:final results from the Spanish Breast Cancer Group 2001-03 phase 2 randomized trial［J］.Cancer,2012,118(1):241-247.
［13］Yip CH,Taib NA.Breast health in developing countries［J］.Climacteric,2014,17(Suppl 2):54-59.
［14］Wang ZF,Wang XD.Consideration and discussion on ten hot issues of endocrine therapy for breast cancer［J］.Chinese J Surger,2015,53(12):895-900.［江泽飞,王晓迪.乳腺癌内分泌治疗十个热点问题的思考［J］.中华外科杂志，2015,53(12):895-900.］
［15］Wang ZF.Decision making for breast cancer:From the individualized treatment to precision medicine plan［J］.Chinese J Practical Surgery,2015,35(7):697-700.［江泽飞.乳腺癌治疗决策：从个体化治疗到精准医学［J］.中国实用外科杂志，2015,35(7):697-700.］
［16］ Li JR,Zhang JM,Ding YH,et al.Anxiety of famale climacteric and health care strategies of menopause［J］.J Practical Gynecol Endocrinol,2018,5(4):42-43.［李家荣,章建梅,丁幼华,等.女性更年期焦虑情况与更年期保健策略分析［J］.实用妇科内分泌电子杂志，2018,5(4)：42-43.］
［17］Maass SW,Roorda C,Berendsen AJ,et al.The prevalence of long-term symptoms of depression and anxiety after breast cancer treatment:Asystematic review［J］.Maturitas,2015,82(1):100-108.
［18］Gambacciani M,Levancini M.Management of postmenopausal osteoporosis and the prevention of fractures［J］.Panminerva Med,2014,56(2):115-131.
［19］Nakatsukasa K,Koyama H,Ouchi Y,et al.Effects of denosumab on bone mineral density in Japanese women with osteoporosis treated with aromatase inhibitors for breast cancer［J］.J Bone Miner Metab,［2018-03-08］.http://dx.doi.org/10.1007/s00774-018-0917-0.
［20］Liu M,Goss PE,Ingle JN,et al.Aromatase inhibitor-associated bone fractures:a case-cohort GWAS and functional genomics［J］.Mol Endocrinol,2014,28(10):1740-1751.
［21］Liu KY.Correlation research on osteoporosis and bone arthritis of postmenopausal women［J］.Chinese J Joint Surgery (Electronic version),2012,6(6):904-907.［刘康妍.绝经后妇女骨质疏松症与骨关节炎的相关性研究［J］.中华关节外科杂志(电子版),2012,6(6):904-907.］
［22］Su G,Xiang Y,He G,et al.Bisphosphonates may protect against bone loss in postmenopausal women with early breast cancer receiving adjuvant aromatase inhibitor therapy:results from a meta-analysis［J］.Arch Med Res,2014,45(7):570-579.
［23］Yang H,Qiu L,Lin JG,et al.Research progress on the treatment of zoledronic acid on breast cancer and the related skeletal metastases［J］.Modern Oncology,2016,24(8):1306-1310.［杨慧,邱玲,林建国,等.唑来膦酸治疗乳腺癌及其骨转移的研究进展［J］.现代肿瘤医学,2016,24(8):1306-1310.］
［24］Gambacciani M,Levancini M.Management of postmenopausal osteoporosis and the prevention of fractures［J］.Panminerva Med,2014,56(2):115-131.
［25］Tella SH,Gallagher JC.Prevention and treatment of postmenopausal osteoporosis［J］.J Steroid Biochem Mol Biol,2014,142:155-170.
［26］Li L,Chen X,Lv S,et al.Influence of exercise on bone remodeling-related hormones and cytokines in ovariectomized rats:a model of postmenopausal osteoporosis［J］.PLoS One,2014,9(11):e112845.
［27］Bai HX,Chang W,Wang XF.A review on risk factors of coronary heart disease in women［J］.Clin J Chinese Med,2017,9(23):142-145.［白贺霞,常玮,王晓峰.女性冠心病危险因素研究现状综述［J］.中医临床研究，2017,9(23):142-145.］
［28］Zhao X,Liu L,Li K,et al.Comparative study on individual aromatase inhibitors on cardiovascular safety profile:a network meta-analysis［J］.Onco Targets Ther,2015,8:2721-2730.
［29］Van Asten K,Neven P,Lintermans A,et al.Aromataseinhibitors in the breast cancer clinic:focus on exemestane［J］.Endocr Relat Cancer,2014,21(1):R31-49.
［30］Yi ZF,Zhu BR.Effects of anastrozole on blood lipid,liver function and safety of breast cancer patients undergoing postoperative chemotherapy［J］.Med Pharmaceutical J Chinese Peopl's Liberation Army,2016,28（8）:72-76.［易哲福,朱碧荣.阿那曲唑对乳腺癌术后化疗患者血脂、肝功能及安全性的影响［J］.解放军医药杂志,2016,28(8):72-76.］
［31］Enlen M,Kocaman SA,Poyraz F,et al.Incremetal effects of serum unicacid levels,autonomic dysfunction,and low-grade inflammation on nocturnal blood pressure in untreated hypertensive patients and normotensive individuals［J］.Turk Kanliyol Dern Ars,2011,39(7):531-539.
［32］Libby P,Okamoto Y,Rocha VZ,et al.Inflammation in atherosclerosis:transition from theory［J］.Circ J,2010,74(2):213-220.
［33］Gao YZ,Gao CY.Correlation of carotid atherosclerosis and coronary heart disease［J］.Chinese J Arteriosclerosis,2015,23(9):942-944.［高瑛子,高传玉.颈动脉硬化与冠心病的相关性［J］.中国动脉硬化杂志，2015,23(9):942-944.］